Cargando…
7.3 Successful use of anakinra, a soluble IL-1 receptor antagonist, in pediatric rheumatic diseases associated macrophage activation syndrome/reactive hemophagocytic lymphohistiocytosis
Autores principales: | Miettunen, PM, Jayanthan, A, Narendran, A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3334169/ http://dx.doi.org/10.1186/1546-0096-6-S1-S13 |
Ejemplares similares
-
Anakinra for the Treatment of Hemophagocytic Lymphohistiocytosis: 21 Cases
por: Baverez, Clara, et al.
Publicado: (2022) -
Successful treatment of cytomegalovirus associated hemophagocytic lymphohistiocytosis with the interleukin 1 inhibitor – anakinra
por: Divithotawela, Chandima, et al.
Publicado: (2015) -
Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis
por: Dimopoulos, George, et al.
Publicado: (2020) -
PB2045: USE OF ANAKINRA IN THE TREATMENT OF ADULT HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: A SYSTEMATIC REVIEW
por: Eshaghpour, Ali, et al.
Publicado: (2023) -
Reactivation of Hemophagocytic Lymphohistiocytosis Triggered by Antithymocyte Globulin
por: Matsuda, Kensuke, et al.
Publicado: (2017)